TTFA-白金结合物:通过评估稳定性-活性关系来解读组合产药的治疗作用
Megha Biswas, Kanishka Chaudhary, Swati Shree Padhi
1Key Laboratory of Novel Materials for Sensor of Zhejiang Province College of Materials and Environmental Engineering, Hangzhou Dianzi University, Hangzhou 310018, China.
Journal of medicinal chemistry
|November 29, 2024
概括
一种新的以为基础的前药,TTFA-Platin,通过平衡有效性和安全性,提供了改进的癌症治疗. 这种新型化合物与现有的白金药物相比,在体内对癌细胞具有更高的效力和更低的毒性.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 材料科学 材料科学 材料科学
背景情况:
- 基于的化疗仍然是癌症治疗的基石.
- 现有的类药物,如思丁和碳丁,在毒性和有效性方面存在局限性.
- 需要新的化合物,具有改进的治疗特征.
研究的目的:
- 推出TTFA-Platin,一种用于增强癌症治疗的新型Pt(II) 前药.
- 评估TTFA-Platin在生物系统中的稳定性,物种化和治疗作用.
- 为了比较TTFA-Platin与对照化合物和现有的白金药物的疗效和毒性.
主要方法:
- 合成和特征的TTFA-Platin和一个控制TMK-Platin.
- 在各种生物介质中进行全面的稳定性和物种化研究.
- 在实验室中对癌症细胞系组进行细胞毒性测定.
- 在体内有毒性评估.
主要成果:
- TTFA-Platin证明了中间的动力学可变性,平衡了有效性和安全性.
- 稳定性和物种化研究绘制了TTFA-Platin的治疗潜力.
- 与TMK-Platin相比,TTFA-Platin对癌症细胞系的效果显著更高.
- 在体内研究显示,TTFA-Platin的毒性明显低于参考化合物.
结论:
- 连接体设计对于微调原药的动力可变性和治疗效益至关重要.
- TTFA-Platin代表了开发更安全,更有效的基癌症治疗的有希望的候选人.
- 这种方法解决了当前化疗药物的局限性,为改进的癌症治疗策略铺平了道路.
相关概念视频
Phase II Reactions: Miscellaneous Conjugation Reactions
41
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
41
Phase II Conjugation Reactions: Overview
159
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
159
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
146
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
146
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K


